Linuo Pharmaceuticals announced that on September 28, 2026, the company submitted an application to the Hong Kong Stock Exchange Limited to issue overseas listed foreign shares and list them on the main board of the Hong Kong Stock Exchange. On the same day, the draft application materials for this issuance and listing were published on the Hong Kong Stock Exchange website. The content contained in the materials may be updated and revised in due course. Only eligible overseas investors and domestic qualified overseas securities investors can subscribe to this offering. The offering and listing is still subject to filing, approval or approval from relevant agencies such as the China Securities Regulatory Commission, the Hong Kong Securities Regulatory Commission and the Hong Kong Stock Exchange, and there is still uncertainty.

Linuo Pharmaceuticals announced that on September 28, 2026, the company submitted an application to the Hong Kong Stock Exchange Limited to issue overseas listed foreign shares and list them on the main board of the Hong Kong Stock Exchange. On the same day, the draft application materials for this issuance and listing were published on the Hong Kong Stock Exchange website. The content contained in the materials may be updated and revised in due course. Only eligible overseas investors and domestic qualified overseas securities investors can subscribe to this offering. The offering and listing is still subject to filing, approval or approval from relevant agencies such as the China Securities Regulatory Commission, the Hong Kong Securities Regulatory Commission and the Hong Kong Stock Exchange, and there is still uncertainty.